Review
Clinical Neurology
Christian Wilson R. Turalde, Adrian Espiritu, Veeda Michelle M. Anlacan
Summary: The study reviewed the efficacy and safety of memantine in multiple sclerosis patients but found no significant improvements in cognitive function, spasticity, fatigue, and disability compared to placebo. Memantine was associated with mild adverse events like dizziness, fatigue, and anxiety. Future research should consider different MS subtypes, co-administration of disease-modifying therapies, longer duration of administration, and more sensitive outcome measures.
FRONTIERS IN NEUROLOGY
(2021)
Review
Clinical Neurology
Fardin Nabizadeh, Mobin Mohamadi, Shayan Rahmani, Rayan Rajabi, Fatemeh Afrashteh, Soroush Najdaghi, Omid Mirmosayyeb
Summary: This study conducted a systematic review and meta-analysis to evaluate the efficacy and safety of cladribine in patients with multiple sclerosis (MS). The results showed that cladribine had a significant impact on treatment outcomes such as progression-free survival and relapse-free survival. However, it did not show significant improvement in reducing the Expanded Disability Status Scale (EDSS). Overall, cladribine appears to be a safe and effective drug for the treatment of relapsing-remitting MS (RRMS) patients.
NEUROLOGICAL SCIENCES
(2023)
Review
Clinical Neurology
Jingyi Tong, Qin Zou, Yongmin Chen, Xiaoping Liao, Rong Chen, Daqi Zhang, Qifu Li
Summary: This network meta-analysis indicated that Amiselimod (0.4 mg) is the most effective treatment strategy as a S1P receptor for MS patients. However, the abovementioned findings need to be further confirmed in the next researches.
NEUROLOGICAL SCIENCES
(2021)
Review
Immunology
Zao Ji, Feifei Jiang
Summary: This study systematically evaluated the clinical efficacy and safety of sublingual immunotherapy for allergic rhinitis. The findings showed that sublingual immunotherapy has better efficacy and safety compared to traditional medicine.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Clinical Neurology
Qi Zhang, Shuqi Zheng, Shuiyan Li, Yuting Zeng, Ling Chen, Gege Li, Shilin Li, Longlong He, Shuping Chen, Xiaoyan Zheng, Jihua Zou, Qing Zeng
Summary: This study analyzed data from 11 randomized controlled trials and found that whole-body vibration (WBV) combined with conventional rehabilitation at a vibration frequency lower than 20 Hz was effective and safe in relieving upper and lower limb spasticity in patients with acute and subacute stroke under the age of 60 years.
FRONTIERS IN NEUROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jinchi Jiang, Chuanqi Chu, Caie Wu, Chen Wang, Chengcheng Zhang, Tiantian Li, Qixiao Zhai, Leilei Yu, Fengwei Tian, Wei Chen
Summary: Probiotics show significant beneficial effects on mental health, insulin resistance, and inflammatory and oxidative stress markers in patients with multiple sclerosis. Both clinical trials and preclinical studies suggest that probiotic intake can reduce the incidence and severity of MS, delay disease progression, and improve symptoms, with favorable effects on immune and inflammatory markers and intestinal microbiome compositions.
Article
Rehabilitation
Jiapeng Huang, Yun Qu, Lini Liu, Kehong Zhao, Ziqi Zhao
Summary: Anodal transcranial direct current stimulation, especially when combined with other therapies and applied for more than 20 minutes, is effective in improving upper limb post-stroke spasticity. Transcranial direct current stimulation is superior to control treatments for subacute and chronic stroke patients under 60. Further high-quality studies are needed to assess its long-term efficacy and safety.
CLINICAL REHABILITATION
(2022)
Article
Food Science & Technology
Federica Novarella, Antonio Carotenuto, Paolo Cipullo, Rosa Iodice, Emanuele Cassano, Antonio Luca Spiezia, Nicola Capasso, Maria Petracca, Fabrizia Falco, Carmine Iacovazzo, Giuseppe Servillo, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia
Summary: This study aimed to evaluate the rate of discontinuation of botulinum toxin (BT) treatment for spasticity in multiple sclerosis (MS) patients and its correlation with MS, spasticity, and injection variables. The study findings suggest that discontinuation of BT treatment is associated with concomitant MS-related issues and cognitive impairment. Shortening the interval between injections can reduce long-term discontinuation.
Review
Pharmacology & Pharmacy
Shisheng Han, Tianwen Yao, Yan Lu, Min Chen, Yanqiu Xu, Yi Wang
Summary: Corticosteroids may induce remission and increase renal survival in IgAN, but adverse reactions should be considered. MMF, TAC, and HCQ might improve proteinuria remission in IgAN treatment, but show no superiority compared to corticosteroids, and the long-term effects need further study.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Clinical Neurology
Katarzyna Sladowska, Pawel Kawalec, Przemyslaw Holko, Oktawia Osiecka
Summary: This study aimed to compare the safety profile of high-efficacy disease-modifying therapies (DMTs) in adult patients with relapsing-remitting multiple sclerosis (RRMS). The results showed that natalizumab and ocrelizumab were the safest DMTs.
NEUROLOGICAL SCIENCES
(2022)
Review
Clinical Neurology
Katarzyna Sladowska, Pawel Kawalec, Przemyslaw Holko, Oktawia Osiecka
Summary: This study compared the safety of high-efficacy disease-modifying therapies in adult patients with relapsing-remitting multiple sclerosis. The results showed that natalizumab and ocrelizumab were the safest options. However, further research is needed to confirm these findings.
NEUROLOGICAL SCIENCES
(2022)
Review
Clinical Neurology
Fardin Nabizadeh, Mona Asghari Ahmadabad, Mobin Mohamadi, Omid Mirmosayyeb, Tahereh Maleki, Kimia Kazemzadeh, Homa Seyedmirzaei
Summary: This study aimed to assess the safety and efficacy of rituximab in patients with multiple sclerosis (MS) by synthesizing all available observational studies and clinical trials. A total of 27 studies were included in the qualitative and quantitative synthesis. The results showed a significant decrease in EDSS score after rituximab treatment, but the reduction in annual relapse rate was not significant. The most common side effect was infection, and the prevalence of malignancies was low. Further randomized controlled trials with long-term follow-up and large sample sizes are needed to confirm the findings.
ACTA NEUROLOGICA BELGICA
(2023)
Article
Medicine, General & Internal
Emmanouil Charitakis, Silvia Metelli, Lars O. Karlsson, Antonios P. Antoniadis, Konstantinos D. Rizas, Ioan Liuba, Henrik Almroth, Anders Hassel Jonsson, Jonas Schwieler, Dimitrios Tsartsalis, Skevos Sideris, Elena Dragioti, Nikolaos Fragakis, Anna Chaimani
Summary: This network meta-analysis compared the efficacy and safety of different catheter ablation strategies for atrial fibrillation. The results showed that combining additional ablation strategies with pulmonary vein isolation (PVI) significantly reduced the risk of recurrence compared to PVI alone, with no significant differences in safety.
Article
Clinical Neurology
Arianna Sartori, Alessandro Dinoto, Lara Stragapede, Giulia Mazzon, Maria Elisa Morelli, Fulvio Pasquin, Alessio Bratina, Antonio Bosco, Paolo Manganotti
Summary: Spasticity is a common and disabling symptom in patients with multiple sclerosis. Both nabiximols and botulinum toxin injections were found to be effective in reducing spasticity and spasms, with botulinum toxin injections potentially more effective on spasms intensity.
NEUROLOGICAL SCIENCES
(2021)
Review
Neurosciences
Denes Kleiner, Istvan Laszlo Horvath, Stefania Bunduc, Dorottya Gergo, Katalin Lugosi, Peter Fehervari, Peter Hegyi, Dezso Csupor
Summary: The systematic review and meta-analysis found that nabiximols is effective in improving refractory spasticity associated with multiple sclerosis (MS) that does not respond to standard treatment. However, further studies are needed to determine the optimal treatment protocol.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Rehabilitation
Rose Goonan, Edward Mohandoss, Celia Marston, Jaqueline Kay, Anurika Priyanjali De Silva, Andrea B. Maier, Esmee Reijnierse, Marlena Klaic
Summary: This study evaluated the physical and functional outcomes of the 'Ending Pyjama Paralysis' intervention in geriatric rehabilitation patients. The results showed that this intervention did not lead to additional functional and physical benefits in this setting.
CLINICAL REHABILITATION
(2024)
Article
Rehabilitation
Sinikka Kilpikoski, Arja H. Hakkinen, Jussi P. Repo, Kati Kyrola, Juhani Multanen, Markku Kankaanpaa, Aki Vainionpaa, Esa-Pekka Takala, Hannu Kautiainen, Jari Ylinen
Summary: This study aimed to compare the effectiveness of a McKenzie Method intervention with guideline-based patient education in patients with sciatica. The results showed that multiple sessions of McKenzie-based back exercises combined with a patient's educational book had similar long-term effects to guideline-based advice. However, the small sample size and confounding factors limited the power of these results.
CLINICAL REHABILITATION
(2024)
Article
Rehabilitation
Margot W. M. de Waal, Michael Jansen, Loes M. Bakker, Arno J. Doornebosch, Elizabeth M. Wattel, Dennis Visser, Ewout B. Smit
Summary: The Utrecht Scale for Evaluation of Rehabilitation has been shown to be effective in evaluating physical and cognitive functioning in geriatric rehabilitation. A minimal important change of 14.5 points has been established for physical functioning.
CLINICAL REHABILITATION
(2024)